Bank of America
EIDX

Bank of America’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Bank of America’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,877
Closed -$2.35M – 8067
2020
Q4 		$2.35M Buy
17,877
+10,464
+141% +$925K ﹤0.01% 3806
2020
Q3 		$374K Sell
7,413
-1,767
-19% -$79.4K ﹤0.01% 4933
2020
Q2 		$437K Buy
9,180
+4,300
+88% +$200K ﹤0.01% 4710
2020
Q1 		$239K Sell
4,880
-1,285
-21% -$65.5K ﹤0.01% 4992
2019
Q4 		$354K Sell
6,165
-6,415
-51% -$318K ﹤0.01% 5252
2019
Q3 		$453K Sell
12,580
-53,308
-81% -$2.08M ﹤0.01% 5153
2019
Q2 		$2.05M Buy
65,888
+62,541
+1,869% +$1.7M ﹤0.01% 4021
2019
Q1 		$79K Sell
3,347
-3,134
-48% -$50.3K ﹤0.01% 5995
2018
Q4 		$89K Buy
6,481
+4,552
+236% +$57.4K ﹤0.01% 5981
2018
Q3 		$19K Buy
1,929
+1,549
+408% +$25.5K ﹤0.01% 6524
2018
Q2 		$8K Buy
+380
New +$7.97K ﹤0.01% 6719

Bank of America's EIDX Position: Q1 2021 in Review

Bank of America sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 17,877 shares — an estimated $2.35M sold.

Bank of America first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $2.35M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Bank of America reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Bank of America sold 17,877 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.35M.
  • Bank of America first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Bank of America's Eidos Therapeutics, Inc. Common Stock position peaked at $2.35M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Bank of America's 13F filing for Q1 2021, filed 14 May 2021.